{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T15:31:58Z","timestamp":1781883118219,"version":"3.54.5"},"reference-count":38,"publisher":"BMJ","issue":"4","funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP 1104756"],"award-info":[{"award-number":["OPP 1104756"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Glob Health"],"accepted":{"date-parts":[[2019,7,12]]},"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Our understanding of the acquisition of intestinal mucosal immunity and the control of poliovirus replication and transmission in later life is still emerging.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>As part of a 2011 randomised, blinded, placebo-controlled clinical trial of the experimental antiviral agent pocapavir (EudraCT 2011-004804-38), Swedish adults, aged 18\u201350 years, who had previously received four doses of inactivated polio vaccine (IPV) in childhood were challenged with a single dose of monovalent oral polio vaccine type 1 (mOPV1). Using faecal samples collected before and serially, over the course of 45 days, after mOPV1 challenge from a subset of placebo-arm participants who did not receive pocapavir (N=12), we investigated the kinetics of the intestinal antibody response to challenge virus by measuring poliovirus type 1-specific neutralising activity and IgA concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>In faecal samples collected prior to mOPV1 challenge, we found no evidence of pre-existing intestinal neutralising antibodies to any of the three poliovirus serotypes. Despite persistent high-titered vaccine virus shedding and rising serum neutralisation responses after mOPV1 challenge, intestinal poliovirus type 1-specific neutralisation remained low with a titer of \u226418.4 across all time points and individuals. Poliovirus types 1-specific, 2-specific and 3-specific IgA remained below the limit of detection for all specimens collected postchallenge.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Interpretation<\/jats:title>\n                  <jats:p>In contrast to recent studies demonstrating brisk intestinal antibody responses to oral polio vaccine challenge in young children previously vaccinated with IPV, this investigation finds that adults previously vaccinated with IPV have only modest intestinal poliovirus type 1-specific neutralisation and no IgA responses that are measurable in stool samples following documented mOPV1 infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjgh-2019-001613","type":"journal-article","created":{"date-parts":[[2019,8,29]],"date-time":"2019-08-29T07:34:08Z","timestamp":1567064048000},"page":"e001613","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":17,"title":["Intestinal antibody responses to a live oral poliovirus vaccine challenge among adults previously immunized with inactivated polio vaccine in Sweden"],"prefix":"10.1136","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0280-2288","authenticated-orcid":false,"given":"Elizabeth B","family":"Brickley","sequence":"first","affiliation":[{"name":"Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK"},{"name":"Epidemiology, Dartmouth College Geisel School of Medicine, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth I","family":"Connor","sequence":"additional","affiliation":[{"name":"Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy F","family":"Wieland-Alter","sequence":"additional","affiliation":[{"name":"Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S","family":"Collett","sequence":"additional","affiliation":[{"name":"ViroDefense Inc, Chevy Chase, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Hartford","sequence":"additional","affiliation":[{"name":"Clinical Trial Center, Sahlgrenska University Hospital, Goteborg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harrie","family":"Van Der Avoort","sequence":"additional","affiliation":[{"name":"Center for Infectious Disease Control, National Institute of Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Austin W","family":"Boesch","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua A","family":"Weiner","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E","family":"Ackerman","sequence":"additional","affiliation":[{"name":"Thayer School of Engineering at Dartmouth, Hanover, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"McKinlay","sequence":"additional","affiliation":[{"name":"Task Force for Global Health, Decatur, Georgia, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minetaro","family":"Arita","sequence":"additional","affiliation":[{"name":"Department of Virology II, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ananda S","family":"Bandyopadhyay","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F","family":"Modlin","sequence":"additional","affiliation":[{"name":"Bill and Melinda Gates Foundation, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F","family":"Wright","sequence":"additional","affiliation":[{"name":"Pediatrics, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,8,28]]},"reference":[{"key":"2025072915112704000_4.4.e001613.1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.15.19"},{"key":"2025072915112704000_4.4.e001613.2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu222"},{"key":"2025072915112704000_4.4.e001613.3","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1586\/14760584.2015.1052800","article-title":"Impact of inactivated poliovirus vaccine on mucosal immunity: implications for the polio eradication endgame","volume":"14","author":"Parker","year":"2015","journal-title":"Expert Rev Vaccines"},{"issue":"Supplement 1","key":"2025072915112704000_4.4.e001613.4","doi-asserted-by":"crossref","first-page":"S228","DOI":"10.1093\/infdis\/175.Supplement_1.S228","article-title":"Humoral and mucosal immunity in infants induced by three sequential inactivated poliovirus vaccine-live attenuated oral poliovirus vaccine immunization schedules. Baltimore area polio vaccine Study Group","volume":"175 Suppl 1","author":"Modlin","year":"1997","journal-title":"J Infect Dis"},{"key":"2025072915112704000_4.4.e001613.5","doi-asserted-by":"crossref","first-page":"5011","DOI":"10.4049\/jimmunol.162.8.5011","article-title":"Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus","volume":"162","author":"Herremans","year":"1999","journal-title":"J Immunol"},{"key":"2025072915112704000_4.4.e001613.6","doi-asserted-by":"publisher","DOI":"10.1086\/605330"},{"key":"2025072915112704000_4.4.e001613.7","doi-asserted-by":"crossref","unstructured":"Praharaj I , Parker EPK , Giri S , et al . Influence of non-polio enteroviruses and the bacterial gut microbiota on oral poliovirus vaccine response: a study from South India. J Infect Dis 2018.","DOI":"10.1093\/infdis\/jiy568"},{"key":"2025072915112704000_4.4.e001613.8","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu182"},{"key":"2025072915112704000_4.4.e001613.9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196810242791701"},{"key":"2025072915112704000_4.4.e001613.10","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/S1473-3099(16)30169-4","article-title":"Vaccine-Induced mucosal immunity to poliovirus: analysis of cohorts from an open-label, randomised controlled trial in Latin American infants","volume":"16","author":"Wright","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025072915112704000_4.4.e001613.11","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/infdis\/jix556","article-title":"Intestinal immune responses to type 2 oral polio vaccine (OPV) challenge in infants previously immunized with bivalent OPV and either high-dose or standard inactivated polio vaccine","volume":"217","author":"Brickley","year":"2018","journal-title":"J Infect Dis"},{"issue":"suppl_1","key":"2025072915112704000_4.4.e001613.12","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1093\/cid\/ciy603","article-title":"Intestinal immunity to poliovirus following sequential trivalent inactivated polio Vaccine\/Bivalent oral polio vaccine and trivalent inactivated polio Vaccine-only immunization schedules: analysis of an open-label, randomized, controlled trial in Chilean infants","volume":"67","author":"Brickley","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025072915112704000_4.4.e001613.13","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1542\/peds.31.4.641","article-title":"Effect of oral poliovirus vaccine in newborn children. II. intestinal resistance and antibody response at 6 months in children fed type I vaccine at birth","volume":"31","author":"Sabin","year":"1963","journal-title":"Pediatrics"},{"key":"2025072915112704000_4.4.e001613.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002599","article-title":"Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge","volume":"8","author":"Hird","year":"2012","journal-title":"PLoS Pathog"},{"key":"2025072915112704000_4.4.e001613.15","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit671"},{"key":"2025072915112704000_4.4.e001613.16","first-page":"976","article-title":"Mucosal immunity following oral poliovirus vaccine and enhanced potency inactivated poliovirus vaccine immunization","volume":"10","author":"Modlin","year":"1991","journal-title":"Pediatr Infect Dis"},{"key":"2025072915112704000_4.4.e001613.17","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/S1473-3099(15)00219-4","article-title":"Inactivated poliovirus vaccine given alone or in a sequential schedule with bivalent oral poliovirus vaccine in Chilean infants: a randomised, controlled, open-label, phase 4, non-inferiority study","volume":"15","author":"O'Ryan","year":"2015","journal-title":"Lancet Infect Dis"},{"key":"2025072915112704000_4.4.e001613.18","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1473-3099(15)00488-0","article-title":"Immunogenicity and safety of a novel monovalent high-dose inactivated poliovirus type 2 vaccine in infants: a comparative, observer-blind, randomised, controlled trial","volume":"16","author":"S\u00e1ez-Llorens","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2025072915112704000_4.4.e001613.19","doi-asserted-by":"crossref","unstructured":"Shulman LM , Gavrilin E , Jorba J , et al . Molecular epidemiology of silent introduction and sustained transmission of wild poliovirus type 1, Israel, 2013. Euro Surveill 2014;19.doi:10.2807\/1560-7917.ES2014.19.7.20709","DOI":"10.2807\/1560-7917.ES2014.19.7.20709"},{"key":"2025072915112704000_4.4.e001613.20","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciu1136"},{"key":"2025072915112704000_4.4.e001613.21","first-page":"124","article-title":"The spread of wild poliovirus in the well-vaccinated Netherlands in connection with the 1978 epidemic","volume":"29","author":"Schaap","year":"1984","journal-title":"Prog Med Virol"},{"key":"2025072915112704000_4.4.e001613.22","first-page":"529","article-title":"The duration of intestinal immunity after an inactivated poliovirus vaccine booster dose in children immunized with oral vaccine: a randomized controlled trial","volume":"215","author":"John","year":"2017","journal-title":"J Infect Dis"},{"key":"2025072915112704000_4.4.e001613.23","doi-asserted-by":"publisher","DOI":"10.1126\/science.1255006"},{"key":"2025072915112704000_4.4.e001613.24","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw542"},{"key":"2025072915112704000_4.4.e001613.25","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05225-11"},{"key":"2025072915112704000_4.4.e001613.26","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1016\/j.vaccine.2013.05.088","article-title":"Development of a simple, rapid, sensitive, high-throughput luciferase reporter based microneutralization test for measurement of virus neutralizing antibodies following respiratory syncytial virus vaccination and infection","volume":"31","author":"Fuentes","year":"2013","journal-title":"Vaccine"},{"key":"2025072915112704000_4.4.e001613.27","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02381-13"},{"key":"2025072915112704000_4.4.e001613.28","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/S1473-3099(17)30236-0","article-title":"Maximising the impact of inactivated polio vaccines","volume":"17","author":"Brickley","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"2025072915112704000_4.4.e001613.29","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/163.1.1"},{"key":"2025072915112704000_4.4.e001613.30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909383"},{"key":"2025072915112704000_4.4.e001613.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.03.005"},{"key":"2025072915112704000_4.4.e001613.32","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis241"},{"key":"2025072915112704000_4.4.e001613.33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1017\/S0022172400055133","article-title":"The response to oral poliovaccine in persons aged 16-18 years","volume":"76","author":"Smith","year":"1976","journal-title":"J Hyg"},{"key":"2025072915112704000_4.4.e001613.34","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiv281"},{"key":"2025072915112704000_4.4.e001613.35","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200535493"},{"key":"2025072915112704000_4.4.e001613.36","doi-asserted-by":"crossref","unstructured":"Wright PF , Hoen AG , Ilyushina NA , et al . Correlates of immunity to influenza as determined by challenge of children with live, attenuated influenza vaccine. Open Forum Infect Dis 2016;3.doi:10.1093\/ofid\/ofw108","DOI":"10.1093\/ofid\/ofw108"},{"key":"2025072915112704000_4.4.e001613.37","doi-asserted-by":"crossref","unstructured":"Brickley EB , Wright PF , Khalenkov A , et al . The effect of preexisting immunity on virus detection and immune responses in a phase II, randomized trial of a Russian-Backbone, live, attenuated influenza vaccine in Bangladeshi children. Clin Infect Dis 2018;35.doi:10.1093\/cid\/ciy1004","DOI":"10.1093\/cid\/ciy1004"},{"key":"2025072915112704000_4.4.e001613.38","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0140-6736(19)31279-6","article-title":"The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study","volume":"394","author":"Van Damme","year":"2019","journal-title":"The Lancet"}],"container-title":["BMJ Global Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjgh-2019-001613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,29]],"date-time":"2025-07-29T22:11:33Z","timestamp":1753827093000},"score":1,"resource":{"primary":{"URL":"https:\/\/gh.bmj.com\/lookup\/doi\/10.1136\/bmjgh-2019-001613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,8,28]]},"published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1136\/bmjgh-2019-001613"],"URL":"https:\/\/doi.org\/10.1136\/bmjgh-2019-001613","relation":{},"ISSN":["2059-7908"],"issn-type":[{"value":"2059-7908","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}